News
A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.
Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...
Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...
GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
Novo Nordisk A/S (NYSE:NVO) develops, manufactures, and distributes pharmaceutical products focused on diabetes, obesity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback